Opinion|Videos|September 30, 2024
Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg
Author(s)Nikolas London, MD, FACS
Fact checked by: Nikolas London, MD, FACS
Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approvals in 2025: What changed and why it matters for ophthalmologists
2
PRIMAvera study: Central vision improvement with subretinal implant
3
Q&A: What changed in residency education in 2025? Perspectives from training directors
4
Refractory dry eye care: How systemic conditions change the game
5